Posttransplant immunosuppression in highly sensitized patients

Research output: Chapter in Book/Report/Conference proceedingChapter

9 Citations (Scopus)

Abstract

Recent desensitization protocols using the combination of plasmapheresis (PP) or immunoadsorption to remove donor-specific anti-HLA antibodies (DSA) and/or intravenous immunoglobulin (IVIG) and rituximab to downregulate antibody-mediated immune responses have made kidney transplantation feasible by abrogating cross-match positivity. Despite good short-term patient and graft survival, acute antibody-mediated rejection (AMR) continued to be an important barrier seen in 20-30% of patients receiving desensitization pro-tocols and it is still not clear which protocol (high-dose IVIG, PP/low-dose IVIG), what type of induction treatment (thymoglobulin, anti-IL-2R antibodies, alemtuzumab), or addition of rituximab is better for the prevention of early acute AMR. Future prospective, multicenter, and randomized trials are required to decide the ideal protocol for sensitized patients.

Original languageEnglish (US)
Title of host publicationContributions to Nephrology
Pages27-34
Number of pages8
Volume162
DOIs
StatePublished - 2009
Externally publishedYes

Publication series

NameContributions to Nephrology
Volume162
ISSN (Print)03025144

Fingerprint

Immunosuppression
Intravenous Immunoglobulins
Plasmapheresis
Antibodies
Graft Survival
Kidney Transplantation
Multicenter Studies
Anti-Idiotypic Antibodies
Down-Regulation
Tissue Donors
Rituximab
Therapeutics

ASJC Scopus subject areas

  • Nephrology

Cite this

Akalin, E. (2009). Posttransplant immunosuppression in highly sensitized patients. In Contributions to Nephrology (Vol. 162, pp. 27-34). (Contributions to Nephrology; Vol. 162). https://doi.org/10.1159/000170810

Posttransplant immunosuppression in highly sensitized patients. / Akalin, Enver.

Contributions to Nephrology. Vol. 162 2009. p. 27-34 (Contributions to Nephrology; Vol. 162).

Research output: Chapter in Book/Report/Conference proceedingChapter

Akalin, E 2009, Posttransplant immunosuppression in highly sensitized patients. in Contributions to Nephrology. vol. 162, Contributions to Nephrology, vol. 162, pp. 27-34. https://doi.org/10.1159/000170810
Akalin E. Posttransplant immunosuppression in highly sensitized patients. In Contributions to Nephrology. Vol. 162. 2009. p. 27-34. (Contributions to Nephrology). https://doi.org/10.1159/000170810
Akalin, Enver. / Posttransplant immunosuppression in highly sensitized patients. Contributions to Nephrology. Vol. 162 2009. pp. 27-34 (Contributions to Nephrology).
@inbook{dc71bb48550243c7beab9e01ac6f1b46,
title = "Posttransplant immunosuppression in highly sensitized patients",
abstract = "Recent desensitization protocols using the combination of plasmapheresis (PP) or immunoadsorption to remove donor-specific anti-HLA antibodies (DSA) and/or intravenous immunoglobulin (IVIG) and rituximab to downregulate antibody-mediated immune responses have made kidney transplantation feasible by abrogating cross-match positivity. Despite good short-term patient and graft survival, acute antibody-mediated rejection (AMR) continued to be an important barrier seen in 20-30{\%} of patients receiving desensitization pro-tocols and it is still not clear which protocol (high-dose IVIG, PP/low-dose IVIG), what type of induction treatment (thymoglobulin, anti-IL-2R antibodies, alemtuzumab), or addition of rituximab is better for the prevention of early acute AMR. Future prospective, multicenter, and randomized trials are required to decide the ideal protocol for sensitized patients.",
author = "Enver Akalin",
year = "2009",
doi = "10.1159/000170810",
language = "English (US)",
isbn = "9783805589451",
volume = "162",
series = "Contributions to Nephrology",
pages = "27--34",
booktitle = "Contributions to Nephrology",

}

TY - CHAP

T1 - Posttransplant immunosuppression in highly sensitized patients

AU - Akalin, Enver

PY - 2009

Y1 - 2009

N2 - Recent desensitization protocols using the combination of plasmapheresis (PP) or immunoadsorption to remove donor-specific anti-HLA antibodies (DSA) and/or intravenous immunoglobulin (IVIG) and rituximab to downregulate antibody-mediated immune responses have made kidney transplantation feasible by abrogating cross-match positivity. Despite good short-term patient and graft survival, acute antibody-mediated rejection (AMR) continued to be an important barrier seen in 20-30% of patients receiving desensitization pro-tocols and it is still not clear which protocol (high-dose IVIG, PP/low-dose IVIG), what type of induction treatment (thymoglobulin, anti-IL-2R antibodies, alemtuzumab), or addition of rituximab is better for the prevention of early acute AMR. Future prospective, multicenter, and randomized trials are required to decide the ideal protocol for sensitized patients.

AB - Recent desensitization protocols using the combination of plasmapheresis (PP) or immunoadsorption to remove donor-specific anti-HLA antibodies (DSA) and/or intravenous immunoglobulin (IVIG) and rituximab to downregulate antibody-mediated immune responses have made kidney transplantation feasible by abrogating cross-match positivity. Despite good short-term patient and graft survival, acute antibody-mediated rejection (AMR) continued to be an important barrier seen in 20-30% of patients receiving desensitization pro-tocols and it is still not clear which protocol (high-dose IVIG, PP/low-dose IVIG), what type of induction treatment (thymoglobulin, anti-IL-2R antibodies, alemtuzumab), or addition of rituximab is better for the prevention of early acute AMR. Future prospective, multicenter, and randomized trials are required to decide the ideal protocol for sensitized patients.

UR - http://www.scopus.com/inward/record.url?scp=59849117803&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59849117803&partnerID=8YFLogxK

U2 - 10.1159/000170810

DO - 10.1159/000170810

M3 - Chapter

C2 - 19001811

AN - SCOPUS:59849117803

SN - 9783805589451

VL - 162

T3 - Contributions to Nephrology

SP - 27

EP - 34

BT - Contributions to Nephrology

ER -